Orviglance (manganese chloride tetrahydrate)
Detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function.
Key Facts
About Ascelia Pharma
Ascelia Pharma is a publicly traded biotech company dedicated to improving the lives of people with rare oncology-related conditions by identifying, developing, and commercializing novel drugs. The company's most advanced asset, Orviglance, has successfully completed a pivotal Phase 3 study and its New Drug Application (NDA) has been accepted for review by the FDA, representing a significant regulatory milestone. With a second candidate, Oncoral, advancing in clinical development and a clear focus on orphan oncology, Ascelia aims to address significant unmet medical needs in areas like liver metastases and gastric cancer.
View full company profile